RxDoctor Payments Data

Christopher Ingram, MD

Infectious Disease · Raleigh, NCNPI 1780647032

Payments from drug & device makers

$1,317in general payments, 2019–2025

Across 66 payments — averaging $19.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$292
  • Viiv Healthcare Company$238
  • Merck$123
  • Shionogi Inc$109
  • Insmed, Inc.$88
  • AbbVie$73
  • plus $394 from 12 others

What the payments were for

  • Food & beverage$1,26696%
  • Education$514%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,317 in reported general payments places this provider in the 65th percentile of 250 infectious disease providers in North Carolina.

See all infectious disease providers in North Carolina

Medicare billing

Part B allowed, 2024
$70,505
Medicare patients
218
Services billed
696

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GenvoyaElviteg/Cob/Emtri/Tenof Alafen39$166,761
BiktarvyBictegrav/Emtricit/Tenofov Ala37$153,423
JulucaDolutegravir/Rilpivirine16$54,645
DovatoDolutegravir Sodium/Lamivudine17$54,357
Daptomycin38$51,576
DescovyEmtricitabine/Tenofov Alafenam13$27,139
TivicayDolutegravir Sodium12$25,422
CeftriaxoneCeftriaxone Sodium76$10,032
Efavirenz-Emtric-Tenofov DisopEfavirenz/Emtricit/Tenofovr Df25$7,378
ErtapenemErtapenem Sodium12$6,304
Cefepime Hcl11$1,036
Fluconazole32$912
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim11$305
Cephalexin17$276
Doxycycline Hyclate14$222

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadGenvoya, Biktarvy, Descovy$292$347,32289 claims
Viiv Healthcare CompanyJuluca, Dovato, Tivicay$238$134,42445 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 250 infectious disease providers in North Carolina.

Other infectious disease in Raleigh

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →